These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31239687)

  • 1. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm.
    Cerveri G; Gesi C; Mencacci C
    Neuropsychiatr Dis Treat; 2019; 15():1525-1535. PubMed ID: 31239687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clozapine versus other atypical antipsychotics for schizophrenia.
    Asenjo Lobos C; Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Leucht S
    Cochrane Database Syst Rev; 2010 Nov; (11):CD006633. PubMed ID: 21069690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review.
    Brasso C; Colli G; Sgro R; Bellino S; Bozzatello P; Montemagni C; Villari V; Rocca P
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review).
    Căpățînă OO; Micluția IV; Fadgyas-Stănculete M
    Exp Ther Med; 2021 Mar; 21(3):276. PubMed ID: 33603883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel.
    Fagiolini A; Alcalá JÁ; Aubel T; Bienkiewicz W; Bogren MMK; Gago J; Cerveri G; Colla M; Sanchez FC; Cuomo A; Helge F; Iacoponi E; Karlsson PA; Peddu P; Pettorruso M; Pereira HJR; Schölin JS; Vernaleken IB
    Ann Gen Psychiatry; 2020; 19():55. PubMed ID: 32999683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study).
    Ivanov SV; Smulevich AB; Voronova EI; Yakhin KK; Beybalaeva TZ; Katok AA
    Front Psychiatry; 2021; 12():770592. PubMed ID: 35140638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia.
    Misiak B; Bieńkowski P; Samochowiec J
    Psychiatr Pol; 2018 Dec; 52(6):971-981. PubMed ID: 30659560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching Clozapine to Cariprazine in Three Patients with Persistent Symptoms of Schizophrenia: A Case Series.
    Duque-Yemail JD; Avila JC
    Neuropsychiatr Dis Treat; 2022; 18():1433-1440. PubMed ID: 35859803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical issues with amisulpride in the management of patients with schizophrenia.
    Pani L; Villagrán JM; Kontaxakis VP; Alptekin K
    Clin Drug Investig; 2008; 28(8):465-77. PubMed ID: 18598092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; Bhoopathi PS; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006627. PubMed ID: 19821380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics.
    Cohrs S
    CNS Drugs; 2008; 22(11):939-62. PubMed ID: 18840034
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.